How to Invest in Coronavirus Vaccine Stocks
Just follow these three simple steps.
Live: Coronavirus Market Crash Coverage
The Motley Fool’s live guide on what investors should do during the stock market crash and the COVID-19 pandemic.
We’ve created this page for all investors seeking advice on what they should be doing in this turbulent period. Our most important content can be found in the Editors' Picks, section.
We do believe this will all end up behind us, because we view investing as a long-term endeavor. Borrowing from Warren Buffett: "We have no idea -- and never have had -- whether the market is going to go up, down, or sideways in the near- or intermediate-term future." However, we firmly believe investors will be rewarded over the long term.
We suggest bookmarking this page as we will update our Editors' Picks periodically -- the Recent Articles section is a live feed of our latest thinking. Finally, we understand that many people are seeking epidemiological information on COVID-19. For that we strictly suggest visiting the information pages set up by the CDC and WHO.
For members of The Motley Fool's investing services, you can access all our Coronavirus market coverage at fool.com/premium after logging in.
Editors' Picks
3 Coronavirus Stocks That Could Double by the End of 2020
Here's exactly how they could realistically pull it off.
10 Ways COVID-19 Will Affect Social Security
The coronavirus pandemic will have a lasting impact on the nation's most important social program.
What If More Than One Company Wins the Coronavirus Vaccine Race?
The ability to globally distribute a vaccine is as important as the vaccine itself. To the best-equipped victors go the spoils.
Recent articles
Got $1,000? 2 Stocks You Can Buy and Hold for Decades
"Forever" may just be a great holding period for these two companies.
No Surprise Here: Moderna's Revenue Skyrockets in Q4
And it will soon soar even more thanks to the strong demand for Moderna's COVID-19 vaccine.
Is Novavax Stock a Buy?
The biotech's growth prospects still appear to clearly outweigh its risks.
1 Big Problem Ocugen Could Face That Investors Might Be Overlooking
This issue won't affect just Ocugen.
Is Fulgent Genetics Still a Good Stock to Buy?
It's a volatile stock right now. But the future for genomic testing looks bright.
Better Buy: Disney vs. Etsy
Take a look at two of the most promising stocks on the market today.
Should Investors Worry About Moderna's Vaccine Delays?
The short answer: No.
2 Reasons Pfizer's COVID Vaccine Prospects Just Got Even Better
The good news keeps on coming.
What Are the Long-Term Prospects for Moderna?
The biotech's messenger RNA platform is promising. But some investors could have qualms about its current valuation.
Are Short-Sellers Right About Inovio?
This straggler in the vaccine race is still facing some struggles -- but there are a couple of bright spots.
Is Sorrento Therapeutics a Good Coronavirus Stock to Buy?
The biotech certainly has plenty of COVID-19 candidates in the hopper.
Is Moderna Stock a Buy?
Here are the short- and long-term answers.
Better Coronavirus Stock: Moderna or Novavax?
There's plenty to like about both of these high-flying biotech stocks.
Will AstraZeneca's Pain Be Johnson & Johnson's Gain?
The two big drugmakers' vaccine fortunes recently went in opposite directions.
Should You Buy Ocugen Stock?
Here's why you might want to -- and why it might not be such a great idea.
Why Ocugen Stock Is Jumping Today
There's continued momentum from the drugmaker's big news announced earlier this month.
Forget Las Vegas Sands, MGM Resorts Is a Better Casino Stock
Casinos still face strong headwinds, but this resort operator has one major defense against them.
1 Big COVID-19 Story That Has Nothing to Do With Vaccines
But this development could be enormously important in fighting COVID-19.
The Important Things to Know About Johnson & Johnson's COVID Vaccine
J&J's new vaccine could be important in ending the pandemic.
Here's Why You Can't Compare Vaccine Results Between Johnson & Johnson, Pfizer, and Moderna
It's simply not an apples-to-apples comparison.